Market Overview

Galena Biopharma Acquires Mills Pharmaceuticals

Galena Biopharma (Nasdaq: GALE) today announced it has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide. Galena expects to pursue the expedited 505(b)(2) regulatory pathway to seek approval of GALE-401 for the treatment of Essential Thrombocythemia (ET). The Company also believes GALE-401 meets the qualifications for orphan drug status. GALE-401 has an estimated peak market size of approximately $200 million in the U.S.

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Most Popular

Related Articles (GALE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free